系统性免疫球蛋白轻链型淀粉样变性的治疗进展

doi:10.35541/cjd.20180845

Abstract

Abstract: 【Abstract】 Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by the? highly organized amyloid fibrillar aggregates that lead to irreversible organ dysfunction. This review summarizes systemic therapies for this disease according to the disease risk stratification. Patients with low-risk systemic immunoglobulin light chain amyloidosis are eligible for chemotherapy combined with autologous hematopoietic stem cell transplantation. Patients with high-risk systemic immunoglobulin light chain amyloidosis can be treated with protease inhibitors (such as bortezomib, carfilzomib and ixazomib), immunomodulatory agents (such as lenalidomide, pomalidomide) and new immunological agents (such as daratumumab and NEOD001).

Key words: Amyloidosis, Immunoglobulin light chains, Clinical protocols

Fu Yujuan, Zhou Jiong, Zheng Min. Treatment of systemic immunoglobulin light chain amyloidosis[J]. Chinese Journal of Dermatology, 2020, 53(8): 668-672.doi:10.35541/cjd.20180845

References ［46］

［1］	Quock TP, Yan T, Chang E, et al. Healthcare resource utilization and costs in amyloid light⁃chain amyloidosis: a real⁃world study using US claims data［J］. J Comp Eff Res, 2018,7（6）:549⁃559. doi: 10.2217/cer⁃2017⁃0100.
［2］	Quock TP, Yan T, Chang E, et al. Epidemiology of AL amyloidosis: a real⁃world study using US claims data［J］. Blood Adv, 2018,2（10）:1046⁃1053. doi: 10.1182/bloodadvances.2018 016402.
［3］	Lousada I, Comenzo RL, Landau H, et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium［J］. Adv Ther, 2015,32（10）:920⁃928. doi: 10.1007/s12325⁃015⁃0250⁃0.
［4］	Andrei M, Wang JC. Cutaneous light chain amyloidosis with multiple myeloma: a concise review［J］. Hematol Oncol Stem Cell Ther, 2018, pii:S1658⁃3876（18）30095⁃5. doi: 10.1016/j.hemonc.2018.09.003.
［5］	Wanat KA, Kim B, Rosenbach M. Multisystem diseases affecting the skin and eye［J］. Clin Dermatol, 2016,34（2）:214⁃241. doi: 10.1016/j.clindermatol.2015.11.013.
［6］	Mahmood S, Bridoux F, Venner CP, et al. Natural history and outcomes in localised immunoglobulin light⁃chain amyloidosis: a long⁃term observational study［J］. Lancet Haematol, 2015,2（6）:e241⁃e250. doi: 10.1016/S2352⁃3026（15）00068⁃X.
［7］	Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N⁃terminal pro⁃brain natriuretic peptide: a staging system for primary systemic amyloidosis［J］. J Clin Oncol, 2004,22（18）:3751⁃3757. doi: 10.1200/JCO.2004.03.029.
［8］	Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes［J］. J Clin Oncol, 2012,30（36）:4541⁃4549. doi: 10.1200/JCO.2011.37.7614.
［9］	Sidiqi MH, Aljama MA, Jevremovic D, et al. Prognostic significance of stringent complete response after stem cell transplantation in immunoglobulin light chain amyloidosis［J］. Biol Blood Marrow Transplant, 2018,24（11）:2360⁃2364. doi: 10.1016/j.bbmt.2018.06.027.
［10］	Nguyen VP, Landau H, Quillen K, et al. Modified high⁃dose melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis［J］. Biol Blood Marrow Transplant, 2018,24（9）:1823⁃1827. doi: 10.1016/j.bbmt.2018.06. 018.
［11］	Afrough A, Saliba RM, Hamdi A, et al. Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic stem cell transplantation［J］. Biol Blood Marrow Transplant, 2018,24（11）:2197⁃2203. doi: 10.1016/j.bbmt.2018.07.010.
［12］	Merlini G. AL amyloidosis: from molecular mechanisms to targeted therapies［J］. Hematology Am Soc Hematol Educ Program, 2017,2017（1）:1⁃12. doi: 10.1182/asheducation⁃2017. 1.1.
［13］	Kumar SK, Dispenzieri A, Lacy MQ, et al. Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation［J］. Blood, 2012,120（21）:3138.
［14］	Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain （AL） amyloidosis［J］. Blood Cancer J, 2017,7（3）:e546. doi: 10.1038/bcj.2017.26.
［15］	Sher T,Gertz MA. Stem cell transplantation for immunoglobulin light chain amyloidosis［J］. Curr Probl Cancer, 2017,41（2）:129⁃137. doi: 10.1016/j.currproblcancer.2017.03.001.
［16］	Landau H, Smith M, Landry C, et al. Long⁃term event⁃free and overall survival after risk⁃adapted melphalan and SCT for systemic light chain amyloidosis［J］. Leukemia, 2017,31（1）:136⁃142. doi: 10.1038/leu.2016.229.
［17］	Browning S, Quillen K, Sloan JM, et al. Hematologic relapse in AL amyloidosis after high⁃dose melphalan and stem cell transplantation［J］. Blood, 2017,130（11）:1383⁃1386. doi: 10. 1182/blood⁃2017⁃06⁃788729.
［18］	Warsame R, Bang SM, Kumar SK, et al. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant［J］. Eur J Haematol, 2014,92（6）:485⁃490. doi: 10.1111/ejh.12282.
［19］	Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long⁃term results of a risk⁃adapted approach［J］. Haematologica, 2014,99（4）:743⁃750. doi: 10.3324/haematol. 2013.095463.
［20］	Kastritis E, Leleu X, Arnulf B, et al. A randomized phaseⅢ trial of Melphalan and Dexamethasone （MDex） versus Bortezomib, Melphalan and Dexamethasone （BMDex） for untreated patients with AL amyloidosis［J］. Blood, 2016,128（22）:646.
［21］	Mikhael JR, Schuster SR, Jimenez⁃Zepeda VH, et al. Cyclophosphamide⁃bortezomib⁃dexamethasone （CyBorD） produces rapid and complete hematologic response in patients with AL amyloidosis［J］. Blood, 2012,119（19）:4391⁃4394. doi: 10.1182/blood⁃2011⁃11⁃390930.
［22］	Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression⁃free survival［J］. Blood, 2012,119（19）:4387⁃4390. doi: 10.1182/blood⁃2011⁃10⁃388462.
［23］	Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis［J］. Blood, 2015,126（5）:612⁃615. doi: 10.1182/blood⁃2015⁃01⁃620302.
［24］	Jaccard A, Comenzo RL, Hari P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment⁃naïve patients with high⁃risk cardiac AL amyloidosis （Mayo Clinic stageⅢ）［J］. Haematologica, 2014,99（9）:1479⁃1485. doi: 10. 3324/haematol.2014.104109.
［25］	Le BF, Molinier⁃Frenkel V, Guellich A, et al. Sequential cyclophosphamide⁃bortezomib⁃dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light⁃chain cardiac amyloidosis［J］. Eur J Cancer, 2017,76:183⁃187. doi: 10.1016/j.ejca.2017.02.004.
［26］	Kastritis E, Gavriatopoulou M, Roussou M, et al. Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib［J］. Blood Cancer J, 2017,7（6）:e570. doi: 10.1038/bcj.2017.47.
［27］	Bochtler T, Hegenbart U, Kunz C, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high⁃dose melphalan: a long⁃term follow⁃up study［J］. Blood, 2016,128（4）:594⁃602. doi: 10.1182/blood⁃2015⁃10⁃676361.
［28］	Bochtler T, Hegenbart U, Kunz C, et al. Translocation t（11;14） is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib⁃based regimens［J］. J Clin Oncol, 2015,33（12）:1371⁃1378. doi: 10.1200/JCO.2014.57.4947.
［29］	Hegenbart U, Bochtler T, Benner A, et al. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long⁃term follow up［J］. Haematologica, 2017,102（8）:1424⁃1431. doi: 10.3324/haematol.2016.163246.
［30］	Tandon N, Sidana S, Gertz MA, et al. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis［J］. Am J Hematol, 2017,92（6）:549⁃554. doi: 10.1002/ajh.24723.
［31］	Mahmood S, Venner CP, Sachchithanantham S, et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens［J］. Br J Haematol, 2014,166（6）:842⁃848. doi: 10. 1111/bjh.12973.
［32］	Sanchorawala V, Shelton AC, Lo S, et al. Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial［J］. Blood, 2016,128（8）:1059⁃1062. doi: 10.1182/blood⁃2016⁃04⁃710822.
［33］	Palladini G, Milani P, Foli A, et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis［J］. Blood, 2017,129（15）:2120⁃2123. doi: 10.1182/blood⁃2016⁃12⁃756528.
［34］	Cohen AD, Scott EC, Liedtke M, et al. A phase I dose⁃escalation study of Carfilzomib in patients with previously⁃treated systemic light⁃chain （al） amyloidosis［J］. Blood, 2014,124（21）:4741.
［35］	Sanchorawala V, Palladini G, Kukreti V, et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis［J］. Blood, 2017,130（5）:597⁃605. doi: 10.1182/blood⁃2017⁃03⁃771220.
［36］	Khouri J, Kin A, Thapa B, et al. Daratumumab proves safe and highly effective in AL amyloidosis［J］. Br J Haematol, 2019,185（2）:342⁃344. doi: 10.1111/bjh.15455.
［37］	Kaufman GP, Schrier SL, Lafayette RA, et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis［J］. Blood, 2017,130（7）:900⁃902. doi: 10.1182/blood⁃2017⁃01⁃763599.
［38］	Sanchorawala V, Sarosiek S, Sloan JM, et al. Safety and tolerability of Daratumumab in patients with relapsed light chain （al） amyloidosis: preliminary results of a phaseⅡ study［J］. Blood, 2017,130（Suppl 1）:507.
［39］	Gran C, Gahrton G, Alici E, et al. Case report: treatment of light⁃chain amyloidosis with daratumumab monotherapy in two patients［J］. Eur J Haematol, 2018,100（4）:386⁃388. doi: 10. 1111/ejh.13008.
［40］	Abeykoon JP, Zanwar S, Dispenzieri A, et al. Daratumumab⁃based therapy in patients with heavily⁃pretreated AL amyloidosis［J］. Leukemia, 2019,33（2）:531⁃536. doi: 10.1038/s41375⁃018⁃0262⁃2.
［41］	Leung N, Thomé SD, Dispenzieri A. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone［J］. Haematologica, 2018,103（3）:e135⁃e137. doi: 10.3324/haematol.2017.183749.
［42］	Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis?［J］. Blood, 2016,128（2）:159⁃168. doi: 10.1182/blood⁃2016⁃01⁃629790.
［43］	Gertz MA, Landau H, Comenzo RL, et al. First⁃in⁃human phase Ⅰ/Ⅱ study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction［J］. J Clin Oncol, 2016,34（10）:1097⁃1103. doi: 10.1200/JCO.2015.63.6530.
［44］	Edwards CV, Gould J, Langer AL, et al. Interim analysis of the phase 1a/b study of chimeric fibril⁃reactive monoclonal antibody 11⁃1F4 in patients with AL amyloidosis［J］. Amyloid, 2017,24（sup1）:58⁃59. doi: 10.1080/13506129.2017.1292900.
［45］	Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component［J］. N Engl J Med, 2015,373（12）:1106⁃1114. doi: 10.1056/NEJMoa1504942.
［46］	Richards DB, Cookson LM, Barton SV, et al. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis［J］. Sci Transl Med, 2018,10（422）. doi: 10.1126/scitranslmed.aan3128.

[1]	Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 55(6): 508-510.
[2]	Environmental and Occupational Skin Disease Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Group on Children, Chinese Society of Dermatology. Expert consensus on clinical application of wet-wrap therapy for atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 289-294.
[3]	Wang Zhaoyang, Chen Anwei, Xiang Xin, Luo Xiaoyan, Xu Zigang, Wang Hua, Ma Lin. An investigation into the current situation of pediatric psoriasis based on the information systems from two children′s hospitals [J]. Chinese Journal of Dermatology, 2022, 55(3): 246-250.
[4]	Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, National Clinical Research Center for Dermatologic and Immunologic Diseases. Chinese Expert consensus on the diagnosis and treatment of adult dermatomyositis （2022） [J]. Chinese Journal of Dermatology, 2022, 55(11): 939-949.
[5]	Skin Tumor Research Center, Chinese Society of Dermatology, Subcommittee on Skin Tumor, China Dermatologist Association. Consensus on diagnosis and treatment of cutaneous squamous cell carcinoma （2021） [J]. Chinese Journal of Dermatology, 2021, 54(8): 653-664.
[6]	Writing committee expert group on “diagnosis and treatment of psoriasis arthropathica: an expert consensus statement in China”. Diagnosis and treatment of psoriatic arthritis: an expert consensus statement in China（2020） [J]. Chinese Journal of Dermatology, 2020, 53(8): 585-595.
[7]	Sexually Transmitted Disease Group, Combination of Traditional and Western Medicine Dermatology. Consensus on diagnosis and treatment of genital herpes by integrated traditional and western medicine （2020） [J]. Chinese Journal of Dermatology, 2020, 53(3): 180-183.
[8]	Chen Binglin, Xue Meijuan, Yang Ji, Li Ming. Diagnosis and treatment of systemic sclerosis-associated interstitial lung disease: current status and advances [J]. Chinese Journal of Dermatology, 2020, 53(1): 66-71.
[9]	Wang Lei, Huang Jun, Shan Yunyun, Xu Ai′e. Reflectance confocal microscopic characteristics of primary cutaneous amyloidosis [J]. Chinese Journal of Dermatology, 2019, 52(4): 265-267.
[10]	Chen Yanqing, Wang Hongsheng. Cutaneous tuberculosis [J]. Chinese Journal of Dermatology, 2019, 52(3): 215-219.
[11]	Yi-Xin LUO Cheng CHI Jie Liu. Dermoscopic features of primary cutaneous amyloidosis [J]. Chinese Journal of Dermatology, 2017, 50(7): 478-481.
[12]	. A case of nodular and macular cutaneous amyloidosis [J]. Chinese Journal of Dermatology, 2008, 41(8): 557-557.
[13]	XU Jin-guo, LU Xian-mei, ZHAO Tian-en. Detection of T and B lymphocytes in lesions of primary cutaneous amyloidosis [J]. Chinese Journal of Dermatology, 2006, 39(10): 581-583.
[14]	LI Xi-qing, XI Li-yan, LIU Hong-fang, LI Bo-you, ZHANG Jun-min, LIN Bao-zhu. Systemic amyloidosis with myopathy as the first manifestation:a case report [J]. Chinese Journal of Dermatology, 2006, 39(1): 44-46.

Treatment of systemic immunoglobulin light chain amyloidosis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［46］

Related Articles 14

Metrics

Comments

Recommended 10